Study of the Prevalence of Autistic Traits in Angelman Syndrome
Launched by IRCCS EUGENIO MEDEA · Mar 21, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how common autism spectrum disorder (ASD) is in children and teenagers who have Angelman syndrome, a genetic condition that affects development. The researchers want to understand the differences between kids with Angelman syndrome who have autism traits and those who do not. They will look at various factors, such as genetics, epilepsy, behavior problems, and how parents manage stress, to see how these might relate to autism traits.
To be eligible for this study, children must be between 4 and 15 years old and have a confirmed diagnosis of Angelman syndrome. Participants will undergo regular assessments that include tests for cognitive development and social skills. Parents will also provide information about their parenting styles and stress levels. The study is currently looking for participants, and it's a great opportunity to contribute to understanding how autism interacts with Angelman syndrome, potentially leading to better support for families.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • genetically confirmed diagnosis of Angelman Syndrome
- • chronological age between 4-15 years
- Exclusion Criteria:
- • genetic examination pending report
- • mental age lower than 12 months
- • brain injury acquired in the peri- or postnatal period
About Irccs Eugenio Medea
IRCCS Eugenio Medea is a leading clinical research institute based in Italy, dedicated to advancing pediatric healthcare through innovative research and evidence-based practices. As a recognized center of excellence, it focuses on multidisciplinary approaches to address complex health challenges in children and adolescents, particularly in the fields of neurodevelopmental disorders, mental health, and rehabilitation. The institute collaborates with national and international partners to conduct rigorous clinical trials, aiming to translate scientific discoveries into effective therapeutic interventions. Committed to enhancing patient outcomes, IRCCS Eugenio Medea prioritizes ethical standards and patient safety in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Conegliano, Treviso, Italy
Patients applied
Trial Officials
Martina Baggio
Principal Investigator
Scientific Institute IRCCS E. Medea, Epilepsy Unit, Conegliano 31015, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported